RESUMEN
BACKGROUND: Patients with end-stage liver disease are prone to hemodynamic disturbances which may be aggravated with liver transplantation. Blood pooling in splanchnic area and portal hypertension cause reduction in central blood volume. Terlipressin reduces mesenteric and hepatic blood flow, causing vasoconstriction in the smooth muscles of the arteries in the splanchnic region. OBJECTIVE: We investigated the efficacy of perioperative terlipressin infusion in patients who received living donor liver transplantation (LDLT) on hepatic and renal functions. DESIGN: Retrospective. SETTING: University hospital. METHOD: The study included 86 adult patients who received LDLT, due to end-stage hepatic disease, between April 2014 and July 2016 in our institute. Data were collected by searching the medical archives of patients. A standard anesthesia protocol was administered to all patients. In a selected group of patients, terlipressin infusion was initiated at 3 µg/kg/h, immediately after anesthesia was induced. The dose was halved following arterial anastomosis and was continued at this dose for the subsequent 3 days. Patients who received terlipressin infusion were compared with patients who did not receive it. MAIN OUTCOME MEASURES: There is no evidence in this trial to show evidence of effectiveness as a result of terlipressin infusion. RESULTS: Patients in the terlipressin group were statistically significantly older. Central venous pressure, cardiac index, global end diastolic volume, and extravascular lung volume did not show significant differences between the groups. Urine output was similar in both groups; however, regarding the use of packed red blood cells and fresh frozen plasma, terlipressin group patients needed more packs. Perioperative liver function tests were similar between the groups except for aspartate aminotransferase and alanine aminotransferase values on the first and third postoperative days. CONCLUSION: Terlipressin infusion was not found to be significantly effective among the liver and kidney function tests. LIMITATIONS: This may be a result of randomization defect of our retrospective study design. Many prospective randomized studies should be planned to reach more accurate results.
Asunto(s)
Circulación Hepática/efectos de los fármacos , Trasplante de Hígado , Donadores Vivos , Lipresina/farmacología , Circulación Renal/efectos de los fármacos , Terlipresina/farmacología , Vasoconstrictores/farmacología , Adulto , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Pruebas de Función Renal , Pruebas de Función Hepática , Masculino , Persona de Mediana Edad , Periodo Posoperatorio , Estudios RetrospectivosRESUMEN
Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
Asunto(s)
Hepatopatías/tratamiento farmacológico , Lipresina/análogos & derivados , Enfermedad Crónica , Humanos , Infusiones Intravenosas , Circulación Hepática/efectos de los fármacos , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/fisiopatología , Hepatopatías/fisiopatología , Lipresina/administración & dosificación , Lipresina/farmacología , Presión Portal/efectos de los fármacos , Circulación Renal/efectos de los fármacos , TerlipresinaRESUMEN
PURPOSE: To study the effects of terlipressin (TP) infusion on systemic perfusion, estimated with pulsed-wave Doppler ultrasonography of systemic arteries, in a population of extremely low birth-weight (ELBW) preterm infants with vasoactive-resistant ductus arteriosus. METHODS: This prospective, observational cohort included, during five years, 12 ELBW infants with hemodynamically significant patent ductus arteriosus and absent or reversed diastolic flow at Doppler ultrasonography of systemic arteries, despite treatment and high-dose vasoactive support. We measured flow velocity of the anterior cerebral, right renal, and superior mesenteric arteries before and after TP infusion. Changes were evaluated by Spearman's rho coefficient analysis, Wilcoxon signed-rank, and Friedman test. RESULTS: Time-averaged mean velocity of the renal artery (P = .028) increased, while renal pulsatility (P = .010) and resistance (P = .004) indexes, and cerebral artery resistance index (P = .021) decreased after TP infusion. Time-averaged mean velocity of the anterior cerebral artery proportionately increased with dopamine dose (rho = 0.678; P = .015), but showed opposite shifts after TP (rho = -0.662; P = .024). CONCLUSIONS: These changes suggest that TP may improve systemic perfusion in the ELBW infants with vasoactive-resistant ductus arteriosus.
Asunto(s)
Arterias Cerebrales/efectos de los fármacos , Conducto Arterioso Permeable/fisiopatología , Lipresina/análogos & derivados , Arteria Mesentérica Superior/efectos de los fármacos , Arteria Renal/efectos de los fármacos , Ultrasonografía Doppler de Pulso/métodos , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Arterias Cerebrales/diagnóstico por imagen , Estudios de Cohortes , Conducto Arterioso Permeable/tratamiento farmacológico , Femenino , Humanos , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro , Lipresina/farmacología , Masculino , Arteria Mesentérica Superior/diagnóstico por imagen , Proyectos Piloto , Estudios Prospectivos , Arteria Renal/diagnóstico por imagen , Terlipresina , Ultrasonografía Doppler de Pulso/efectos de los fármacos , Vasoconstrictores/farmacologíaRESUMEN
BACKGROUND: Focal hepatic venous outflow obstruction frequently occurs after extended liver resection and leads to a portal hypertension, arterial hypoperfusion and parenchymal necrosis. In this study, we investigated the pharmacological modulation of liver perfusion and hepatic damage in a surgical model of hepatic outflow obstruction after extended liver resection by administration of 5 different drugs in comparison to an operative intervention, splenectomy. METHODS: Male inbred Lewis rats (Lew/Crl) were subjected to right median hepatic vein ligation + 70% partial hepatectomy. Treatment consisted of a splenectomy or the application of saline, carvedilol or isosorbide-5-mononitrate (ISMN) (5 mg · kg-1 respectively 7,2 mg · kg-1 per gavage 12 h-1). The splenectomy was performed during operation. The effect of the treatments on hepatic hemodynamics were measured in non-operated animals, immediately after operation (n = 4/group) and 24 h after operation (n = 5/group). Assessment of hepatic damage (liver enzymes, histology) and liver cell proliferation (BrdU-immunohistochemistry) was performed 24 h after operation. Furthermore sildenafil (10 µg · kg-1 i.p. 12h-1), terlipressin (0.05 mg · kg-1 i.v. 12 h-1) and octreotide (10 µg · kg-1 s.c. 12 h-1) were investigated regarding their effect on hepatic hemodynamics and hepatic damage 24 h after operation (n = 4/group). RESULTS: Carvedilol and ISMN significantly decreased the portal pressure in normal non-operated rats from 11,1 ± 1,1 mmHg (normal rats) to 8,4 ± 0,3 mmHg (carvedilol) respectively 7,4 ± 1,8 mmHg (ISMN). ISMN substantially reduced surgery-induced portal hypertension from 15,4 ± 4,4 mmHg to 9,6 ± 2,3 mmHg. Only splenectomy reduced the portal flow immediately after operation by approximately 25%. No treatment had an immediate effect on the hepatic arterial perfusion. In all treatment groups, portal flow increased by approximately 3-fold within 24 h after operation, whereas hepatic arterial flow decreased substantially. Neither treatment reduced hepatic damage as assessed 24 h after operation. The distribution of proliferating cells appeared very similar in all drug treated groups and the splenectomy group. CONCLUSION: Transient relative reduction of portal pressure did not result in a reduction of hepatic damage. This might be explained by the development of portal hyperperfusion which was accompanied by arterial hypoperfusion.
Asunto(s)
Hepatectomía , Hígado/irrigación sanguínea , Animales , Antihipertensivos/farmacología , Carbazoles/farmacología , Carvedilol , Dinitrato de Isosorbide/análogos & derivados , Dinitrato de Isosorbide/farmacología , Hígado/efectos de los fármacos , Hígado/cirugía , Lipresina/análogos & derivados , Lipresina/farmacología , Masculino , Octreótido/farmacología , Presión Portal/efectos de los fármacos , Propanolaminas/farmacología , Ratas Endogámicas Lew , Citrato de Sildenafil/farmacología , Esplenectomía , Terlipresina , Vasoconstrictores/farmacología , Vasodilatadores/farmacologíaRESUMEN
BACKGROUND: Vasopressin (AVP) and terlipressin (TP) have been used as last-line therapy in refractory shock in children. However, the efficacy and safety profiles of AVP and TP have not been determined in pediatric refractory shock of different origins. We aimed to assess the efficacy and safety of the addition of AVP/TP therapy in pediatric refractory shock of all causes compared to conventional therapy with fluid resuscitation and vasopressor and inotropic therapy. METHODS: We conducted a systematic review, meta-analysis, and trial sequential analysis (TSA) comparing AVP and TP to conventional therapy. MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov were searched up to February 2016. The systematic review included all reports of AVP/TP use in the pediatric population. Reports of clinical trials were pooled using random-effects models and TSA. Main outcomes were mortality and tissue ischemia. RESULTS: Three randomized controlled trials and five "before-and-after clinical" trials (without comparator) met the inclusion criteria. Among 224 neonates and children (aged 0 to 18 years) with refractory shock, 152 received therapy with AVP or TP. Pooled analyses showed no association between AVP/TP treatment and mortality (relative risk (RR),1.19; 95% confidence interval (CI), 0.71-2.00), length of stay in the pediatric intensive care unit (PICU) (mean difference (MD), -3.58 days; 95% CI, -9.05 to 1.83), and tissue ischemia (RR, 1.48; 95% CI, 0.47-4.62). In TSA, no significant effect on mortality and risk for developing tissue ischemia was observed with AVP/TP therapy. CONCLUSION: Our results emphasize the lack of observed benefit for AVP/TP in terms of mortality and length of stay in the PICU, and suggest an increased risk for ischemic events. Our TSA suggests that further large studies are necessary to demonstrate and establish benefits of AVP/TP in children. PROSPERO registry: CRD42016035872.
Asunto(s)
Apoyo Vital Cardíaco Avanzado/métodos , Pediatría/métodos , Choque/tratamiento farmacológico , Vasoconstrictores/farmacología , Adolescente , Niño , Preescolar , Humanos , Lactante , Recién Nacido , Tiempo de Internación , Lipresina/análogos & derivados , Lipresina/farmacología , Lipresina/uso terapéutico , Pediatría/tendencias , Choque/mortalidad , Terlipresina , Vasoconstrictores/uso terapéutico , Vasopresinas/farmacología , Vasopresinas/uso terapéuticoRESUMEN
Terlipressin has been used extensively in the management of certain complications associated with end-stage liver diseases (ESLDs). In our pilot study, terlipressin treatment showed beneficial effects on liver function in patients with decompensated cirrhosis, however whether it plays a role in liver ischemia-reperfusion injury (IRI) remains unknown. Using a mouse nonlethal hepatic IR model, we found terlipressin administration significantly ameliorated IR-induced liver apoptosis, necrosis and inflammation. Furthermore, despite its known effect on visceral vasoconstriction, hemodynamic evaluation of murine hepatic tissue after IR revealed no change of overall hepatic blood flow after terlipressin treatment. Further studies identified the upregulation of vasopressin receptor 1 (V1R) expression on hepatocytes upon IR. In isolated hepatocyte hypoxia/reoxygenation model, the active component of terlipressin, lysine vasopressin, conferred hepatocytes resistant to oxidative stress-induced apoptosis. Mechanistic studies revealed the V1R engagement activated the Wnt/ß-catenin/FoxO3a/AKT pathway, which subsequently circumvented the proapoptotic events, thus ameliorated hepatocyte apoptosis. Furthermore, genetic knockdown of V1R expression in hepatocyte cell lines or blockade of this signaling pathway abrogated such protective effect. CONCLUSION: These data highlight the functional importance of the hepatocyte V1R/Wnt/ß-catenin/FoxO3a/AKT pathway in protecting liver from oxidative stress-induced injury.
Asunto(s)
Hepatocitos/metabolismo , Hígado/metabolismo , Receptores de Vasopresinas/metabolismo , Daño por Reperfusión/fisiopatología , Animales , Apoptosis/efectos de los fármacos , Citoprotección/fisiología , Proteína Forkhead Box O3/metabolismo , Hepatocitos/efectos de los fármacos , Humanos , Hígado/efectos de los fármacos , Hígado/fisiopatología , Lipresina/farmacología , Masculino , Ratones Endogámicos C57BL , Proteínas Proto-Oncogénicas c-akt/metabolismo , Interferencia de ARN , Receptores de Vasopresinas/genética , Receptores de Vasopresinas/fisiología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Vasoconstrictores/farmacología , Vía de Señalización Wnt/efectos de los fármacosRESUMEN
Terlipressin is recommended as a gold standard to treat hepatorenal syndrome complicating liver cirrhosis. It is presented as a specific V1A receptor agonist, beyond its enzymatic conversion into lysine8-Vasopressin (LVP), able to counteract the splanchnic vasodilation. However, the complete pharmacological characterization of this drug with respect to the different vasopressin receptor subtypes is missing. We studied terlipressin intrinsic properties, focusing not only on V1A, but also on other vasopressin receptor subtypes. The experimental studies were conducted on rat and human cellular models. Binding experiments were performed on rat liver membranes and CHO cells transfected with the different human vasopressin receptor subtypes. Agonist status was assessed from inositol phosphate or cyclic AMP assays, and measurement of intracellular calcium variations, performed on cultured vascular smooth muscle cells from rat aorta and human uterine artery and CHO cells. Terlipressin binds to the rat and human V1A receptors with an affinity in the micromolar range, a value 120 fold lower than that of LVP. It induces a rapid and transient intracellular calcium increase, a robust stimulation of phospholipase C but with reduced maximal efficiencies as compared to LVP, indicating a partial V1A agonist property. In addition, terlipressin is also a full agonist of human V2 and V1B receptors, with also a micromomolar affinity. CONCLUSIONS: Terlipressin is a non-selective vasopressin analogue, exhibiting intrinsic agonist properties. Its full V2 receptor agonism may result in renal effects potentially aggravating water retention and hyponatremia of cirrhosis.
Asunto(s)
Síndrome Hepatorrenal/tratamiento farmacológico , Lipresina/análogos & derivados , Profármacos/farmacología , Receptores de Vasopresinas/agonistas , Animales , Células CHO , Línea Celular , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Síndrome Hepatorrenal/metabolismo , Humanos , Fosfatos de Inositol/metabolismo , Cirrosis Hepática/metabolismo , Lipresina/farmacología , Masculino , Ratas , Ratas Wistar , Terlipresina , Transfección/métodos , Vasopresinas/efectos de los fármacos , Vasopresinas/metabolismoRESUMEN
Liver cirrhosis is a major cause of morbidity and mortality worldwide, mainly due to complications of portal hypertension. In this article, we review the current understanding on the pathophysiology, the diagnostic criteria and the available therapeutic options for patients with emerging hepatic syndromes in cirrhosis, namely the hepatorenal, hepato-adrenal and hepatopulmonary syndrome. The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed. The hepatopulmonary syndrome is often missed in the evaluation of patients with cirrhosis; however, early recognition is essential for the efficient management of individual patients. The hepato-adrenal syndrome, although not fully characterized, offers an exciting field for research and potential therapeutic interventions.
Asunto(s)
Síndrome Hepatorrenal/complicaciones , Hipertensión Portal/complicaciones , Cirrosis Hepática/fisiopatología , Lesión Renal Aguda/etiología , Insuficiencia Suprarrenal/complicaciones , Insuficiencia Suprarrenal/etiología , Ascitis/complicaciones , Ascitis/etiología , Creatinina/orina , Medicina Basada en la Evidencia/métodos , Síndrome Hepatorrenal/etiología , Síndrome Hepatorrenal/fisiopatología , Humanos , Hipertensión Portal/fisiopatología , Cirrosis Hepática/complicaciones , Cirrosis Hepática/etiología , Trasplante de Hígado , Lipresina/análogos & derivados , Lipresina/farmacología , Lipresina/uso terapéutico , Midodrina/farmacología , Midodrina/uso terapéutico , Norepinefrina/farmacología , Norepinefrina/uso terapéutico , Octreótido/farmacología , Octreótido/uso terapéutico , Sustitutos del Plasma/farmacología , Sustitutos del Plasma/uso terapéutico , Derivación Portosistémica Intrahepática Transyugular , Albúmina Sérica/farmacología , Albúmina Sérica/uso terapéutico , Terlipresina , Vasodilatadores/farmacología , Vasodilatadores/uso terapéutico , Vasopresinas/farmacología , Vasopresinas/uso terapéuticoRESUMEN
BACKGROUND: Hypouricemia is pathognomonic in syndrome of inappropriate secretion of antidiuretic hormone (SIADH) but the underlying mechanism remains unclear. Based on the previous studies, we hypothesized that V1a receptor may play a principal role in inducing hypouricemia in SIADH and examined uric acid metabolism using a rat model. METHODS: Terlipressin (25 ng/h), a selective V1a agonist, was subcutaneously infused to 7-week-old male Wistar rats (n = 9). Control rats were infused with normal saline (n = 9). The rats were sacrificed to obtain kidney tissues 3 days after treatment. In addition to electrolyte metabolism, changes in expressions of the urate transporters including URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2 and NPT1 (SLC17A1) were examined by western blotting and immunohistochemistry. RESULTS: In the terlipressin-treated rats, serum uric acid (UA) significantly decreased and the excretion of urinary UA significantly increased, resulting in marked increase in fractional excretion of UA. Although no change in the expression of URAT1, GLUT9 expression significantly decreased whereas the expressions of ABCG2 and NPT1 significantly increased in the terlipressin group. The results of immunohistochemistry corroborated with those of the western blotting. Aquaporin 2 expression did not change in the medulla, suggesting the independence of V2 receptor stimulation. CONCLUSION: Stimulation of V1a receptor induces the downregulation of GLUT9, reabsorption urate transporter, together with the upregulation of ABCG2 and NPT1, secretion urate transporters, all changes of which clearly lead to increase in renal UA clearance. Hypouricemia seen in SIADH is attributable to V1a receptor stimulation.
Asunto(s)
Síndrome de Secreción Inadecuada de ADH/complicaciones , Transportadores de Anión Orgánico/fisiología , Receptores de Vasopresinas/fisiología , Defectos Congénitos del Transporte Tubular Renal/etiología , Ácido Úrico/metabolismo , Cálculos Urinarios/etiología , Transportador de Casetes de Unión a ATP, Subfamilia G, Miembro 2/fisiología , Animales , Acuaporina 2/análisis , Acuaporina 2/fisiología , Lipresina/análogos & derivados , Lipresina/farmacología , Masculino , Tasa de Depuración Metabólica , Proteínas de Transporte de Monosacáridos/análisis , Proteínas de Transporte de Monosacáridos/fisiología , Ratas , Ratas Wistar , Proteínas Cotransportadoras de Sodio-Fosfato de Tipo III/fisiología , TerlipresinaRESUMEN
Terlipressin (TP), an analog of arginine vasopressin, was reported beneficial in sepsis patients when combined use with norepinephrine (NE), but the undetermined action, mechanism, and safety limited it to become the first-line vasopressor for sepsis patients. With 32 septic shock patients, we investigated the effects of a small dose of TP (1.3 µg/kg/h) on hemodynamic, tissue blood flow, vital organ function, acid-base balance, and coagulation function to systemically know the beneficial effect and side effects of TP on septic shock. The results showed that as compared with the single use of NE group (17 patients), a small dose of TP (1.3 µg/kg/h) in combination with NE continuous infusion, except for decreasing the mortality and NE requirement, could better improve and stabilize the hemodynamics, improve the tissue blood flow, increase the blood oxygen saturation and urine volume, and decrease the lactate level and complication rate (47% versus 82.3% in NE group). Meanwhile, TP + NE did not induce blood bilirubin increase and platelet count decrease and hyponatremia that vasopressin has. The results show that low dose of TP continuous infusion can help NE achieve the good resuscitation effect by improving tissue blood flow, stabilizing hemodynamics, and protecting organ function in septic shock patients while did not induce the side effects that high dose or bonus of TP or vasopressin induced. Low dose of TP may be recommended as the first-line vasopressor for refractory hypotension after severe sepsis or septic shock.
Asunto(s)
Lipresina/análogos & derivados , Flujo Sanguíneo Regional/efectos de los fármacos , Sepsis/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Equilibrio Ácido-Base/efectos de los fármacos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Coagulación Sanguínea/efectos de los fármacos , Método Doble Ciego , Esquema de Medicación , Quimioterapia Combinada , Femenino , Hemodinámica/efectos de los fármacos , Humanos , Infusiones Intravenosas , Lipresina/farmacología , Lipresina/uso terapéutico , Masculino , Persona de Mediana Edad , Norepinefrina/uso terapéutico , Sepsis/fisiopatología , Terlipresina , Resultado del Tratamiento , Vasoconstrictores/farmacología , Adulto JovenRESUMEN
BACKGROUND: Recent studies have shown the efficacy of terlipressin on postoperative renal function in patients who have undergone living donor liver transplantation (LDLT). OBJECTIVES: To evaluate the effect of perioperative terlipressin on postoperative renal function in patients who have undergone LDLT and to analyze the hemodynamic data during transplantation surgery. STUDY DESIGN: A meta-analysis. METHODS: We assessed the postoperative peak serum creatinine level and changes in the hemodynamic data (e.g. the mean arterial pressure, heart rate, and systemic vascular resistance). We collected randomized controlled trials from PubMed, EMBASE Drugs and Pharmacology, Cochrane Controlled Trials Register, and Cochrane Database on Systematic Reviews. Analysis was conducted using RevMan 5.2. Data from each trial were pooled and weighted by their mean differences and corresponding 95% confidence intervals (CI). A heterogeneity assessment was performed. RESULTS: Three trials (151 patients) were included. The difference in the mean (95% CI) peak serum creatinine (mg/dL) levels postoperatively was not significant between the intervention and control groups (weighted mean difference [WMD]: -0.27; CI: -0.55-0.01; P = .06). Terlipressin significantly decreased heart rate during the anhepatic phase (WMD: -6.58; 95% CI: -8.85 to -4.31; P < .00001) with a low heterogeneity (I(2) = 41%) and significantly decreased heart rate during the neohepatic phase (WMD: -9.82; 95% CI: -11.96 to -7.68; P < .00001), although the heterogeneity was high (I(2) > 50%). CONCLUSIONS: An intravenous infusion of terlipressin perioperatively for LDLT has no effect on the creatinine values postoperatively. Larger randomized controlled trials on terlipressin infusions during liver transplantation are needed.
Asunto(s)
Creatinina/sangre , Hemodinámica/efectos de los fármacos , Trasplante de Hígado/métodos , Lipresina/análogos & derivados , Circulación Renal/efectos de los fármacos , Vasoconstrictores/farmacología , Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Infusiones Intravenosas , Donadores Vivos , Lipresina/farmacología , Lipresina/uso terapéutico , Atención Perioperativa , Periodo Posoperatorio , Ensayos Clínicos Controlados Aleatorios como Asunto , Terlipresina , Vasoconstrictores/uso terapéuticoRESUMEN
INTRODUCTION: We investigated whether treatment with terlipressin during recovery from hypotension due to haemorrhagic shock (HS) is effective in restoring cerebral perfusion pressure (CPP) and brain tissue markers of water balance, oxidative stress and apoptosis. METHODS: In this randomised controlled study, animals undergoing HS (target mean arterial pressure (MAP) 40 mmHg for 30 minutes) were randomised to receive lactated Ringer's solution (LR group; n =14; volume equal to three times the volume bled), terlipressin (TERLI group; n =14; 2-mg bolus), no treatment (HAEMO group; n =12) or sham (n =6). CPP, systemic haemodynamics (thermodilution technique) and blood gas analyses were registered at baseline, shock and 5, 30, 60 (T60), 90 and 120 minutes after treatment (T120). After the animals were killed, brain tissue samples were obtained to measure markers of water balance (aquaporin-4 (AQP4)), Na(+)-K(+)-2Cl(-) co-transporter (NKCC1)), oxidative stress (thiobarbituric acid reactive substances (TBARS) and manganese superoxide dismutase (MnSOD)) and apoptotic damage (Bcl-x and Bax). RESULTS: Despite the HS-induced decrease in cardiac output (CO) and hyperlactataemia, resuscitation with terlipressin recovered MAP and resulted in restoration of CPP and in cerebral protection expressed by normalisation of AQP4, NKCC1, TBARS and MnSOD expression and Bcl-x/Bax ratio at T60 and T120 compared with sham animals. In the LR group, CO and blood lactate levels were recovered, but the CPP and MAP were significantly decreased and TBARS levels and AQP4, NKCC1 and MnSOD expression and Bcl-x/Bax ratio were significantly increased at T60 and T120 compared with the sham group. CONCLUSIONS: During recovery from HS-induced hypotension, terlipressin was effective in normalising CPP and cerebral markers of water balance, oxidative damage and apoptosis. The role of this pressor agent on brain perfusion in HS requires further investigation.
Asunto(s)
Circulación Cerebrovascular/efectos de los fármacos , Hipotensión/tratamiento farmacológico , Lipresina/análogos & derivados , Choque Hemorrágico/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Animales , Modelos Animales de Enfermedad , Fluidoterapia , Hemodinámica/efectos de los fármacos , Hipotensión/etiología , Lipresina/farmacología , Lipresina/uso terapéutico , Choque Hemorrágico/complicaciones , Porcinos , Terlipresina , Vasoconstrictores/farmacologíaRESUMEN
INTRODUCTION: In series of cases and animal models suffering hemorrhagic shock, the use of vasopressors has shown potential benefits regarding hemodynamics and tissue perfusion. Terlipressin is an analogue of vasopressin with a longer half-life that can be administered by bolus injection. We have previously observed that hypertonic albumin improves resuscitation following controlled hemorrhage in piglets. The aim of the present study was to analyze whether the treatment with the combination of terlipressin and hypertonic albumin can produce better hemodynamic and tissular perfusion parameters than normal saline or hypertonic albumin alone at early stages of hemorrhagic shock in an infant animal model. METHODS: Experimental, randomized animal study including 39 2-to-3-month-old piglets. Thirty minutes after controlled 30 ml/kg bleed, pigs were randomized to receive either normal saline (NS) 30 ml/kg (n = 13), 5% albumin plus 3% hypertonic saline (AHS) 15 ml/kg (n = 13) or single bolus of terlipressin 15 µg/kg i.v. plus 5% albumin plus 3% hypertonic saline 15 ml/kg (TAHS) (n = 13) over 30 minutes. Global hemodynamic and tissular perfusion parameters were compared. RESULTS: After controlled bleed a significant decrease of blood pressure, cardiac index, central venous saturation, carotid and peripheral blood flow, brain saturation and an increase of heart rate, gastric PCO2 and lactate was observed. After treatment no significant differences in most hemodynamic (cardiac index, mean arterial pressure) and perfusion parameters (lactate, gastric PCO2, brain saturation, cutaneous blood flow) were observed between the three therapeutic groups. AHS and TAHS produced higher increase in stroke volume index and carotid blood flow than NS. CONCLUSIONS: In this pediatric animal model of hypovolemic shock, albumin plus hypertonic saline with or without terlipressin achieved similar hemodynamics and perfusion parameters than twice the volume of NS. Addition of terlipressin did not produce better results than AHS.
Asunto(s)
Albúminas/uso terapéutico , Hipovolemia/tratamiento farmacológico , Lipresina/análogos & derivados , Solución Salina Hipertónica/uso terapéutico , Cloruro de Sodio/uso terapéutico , Albúminas/farmacología , Animales , Animales Recién Nacidos , Presión Sanguínea/efectos de los fármacos , Dióxido de Carbono/metabolismo , Modelos Animales de Enfermedad , Frecuencia Cardíaca/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Hemorragia/patología , Hemorragia/fisiopatología , Hipovolemia/fisiopatología , Lipresina/farmacología , Lipresina/uso terapéutico , Oxígeno/sangre , Solución Salina Hipertónica/farmacología , Cloruro de Sodio/farmacología , Volumen Sistólico/efectos de los fármacos , Sus scrofa , TerlipresinaRESUMEN
BACKGROUND: Septic shock is still related to unacceptably high morbidity and mortality. Microcirculatory alteration has been demonstrated to be one important reason associated with this evolution. Vasoactive drugs are often used to restore adequate arterial pressure and tissue perfusion in septic shock. To define the roles of different drugs, the effects of terlipressin (TP) on the microcirculation of small bowel mesentery in rats with endotoxic shock were evaluated and compared with those of norepinephrine (NE). METHODS: Twenty-five adult male Wistar rats were randomized to the control (n = 5), TP (n = 10), and NE (n = 10) groups. After endotoxic shock was induced by intravenous lipopolysaccharide administration for 30 min, rats in the NE and TP groups were infused with saline 5 mL/kg/h and simultaneously given NE 4 µg/kg/min or TP 8 µg/kg/h. The mean arterial pressure, heart rate, blood gas analysis, and microvascular blood flow images of small bowel mesentery were recorded. RESULTS: After fluid resuscitation and vasopressor infusion, the mean arterial pressure was restored to the baseline values in the NE and TP groups. In the TP group, the heart rate was significantly lower compared with the NE group (P = 0.013). The proportion of perfused vessels and the microvascular flow index (MFI) were significantly increased; furthermore, the heterogeneity index of small vessels was markedly decreased in both the interventional groups with respect to the control group. Compared with the NE group, the MFI was significantly higher (P < 0.05) and the heterogeneity index was significantly lower (P < 0.05) in the TP group. CONCLUSIONS: Both TP and NE improved hemodynamic and microcirculatory alterations in rats with endotoxic shock. Compared with NE, TP was more effective in promoting MFI and improving the heterogeneity of small bowel mesentery in rats.
Asunto(s)
Lipresina/análogos & derivados , Microcirculación/efectos de los fármacos , Choque Séptico/tratamiento farmacológico , Circulación Esplácnica/efectos de los fármacos , Vasoconstrictores/uso terapéutico , Equilibrio Ácido-Base , Animales , Evaluación Preclínica de Medicamentos , Hemodinámica , Lipresina/farmacología , Lipresina/uso terapéutico , Masculino , Norepinefrina , Oxígeno/sangre , Distribución Aleatoria , Ratas Wistar , Choque Séptico/fisiopatología , Terlipresina , Vasoconstrictores/farmacologíaRESUMEN
Nitric oxide (NO) participates in shock and poorer portal hypotensive effect to vasoconstrictors in portal hypertension with hemorrhage, the so-called splanchnic hyposensitivity. Relative adrenal insufficiency accompanies hemorrhagic shock and is found in liver disease, the 'hepatoadrenal syndrome', but the relevant interactions remain unsettled. Portal hypertensive rats were induced by partial portal vein ligation (PVL). Experiments were performed on the 14th day post PVL: (I) ACTH stimulation test for rats without or with hemorrhage; (II) Glypressin response (mean arterial pressure, MAP; portal pressure, PP) in rats (a) without hemorrhage or with hemorrhage, injected with (b) distilled water (DW), (c) dexamethasone 3 mg/kg; (III) To survey the dose-dependent effects of glucocorticoid without being confounded by endogenous adrenal hormone, glypressin response was surveyed in PVL rats with adrenalectomy: (a) without hemorrhage or with hemorrhage, injected with (b) DW; (c) dexamethasone 3 mg/kg; (d) dexamethasone 5 mg/kg. Plasma tumor necrosis factor-α (TNF-α) concentrations and abdominal aorta (AA), superior mesenteric artery (SMA) NO synthases (NOS) mRNA expressions were determined. The results showed that ACTH induced corticosterone release similarly in PVL rats with or without hemorrhage. In bleeding PVL rats, dexamethasone (1) down-regulated AA NOS and enhanced glypressin-induced MAP elevation; (2) did not influence glypressin-induced PP reduction; (3) reduced TNF-α. In bleeding PVL and adrenalectomized rats, high-dose dexamethasone (1) down-regulated AA/SMA NOS; (2) enhanced glypressin-induced MAP elevation and PP reduction; (3) reduced TNF-α. In conclusion, bleeding portal hypertensive rats failed to enhance corticosterone release, suggesting a relative adrenal insufficiency. High-dose dexamethasone reversed systemic hypotension and splanchnic hyporesponsiveness to glypressin in adrenalectomized PVL rats accompanied by TNF-α and NOS down-regulation, suggesting the importance of adequate adrenocorticoid supplement in portal hypertension with hemorrhage and adrenal dysfunction.
Asunto(s)
Glándulas Suprarrenales/fisiopatología , Hemorragia/complicaciones , Hipertensión Portal/complicaciones , Hipertensión Portal/fisiopatología , Glándulas Suprarrenales/efectos de los fármacos , Animales , Aorta Abdominal/efectos de los fármacos , Aorta Abdominal/metabolismo , Peso Corporal/efectos de los fármacos , Corticosterona/biosíntesis , Dexametasona/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hemodinámica/efectos de los fármacos , Hipertensión Portal/sangre , Hipertensión Portal/metabolismo , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Sistema Hipotálamo-Hipofisario/fisiopatología , Lipresina/análogos & derivados , Lipresina/farmacología , Masculino , Arteria Mesentérica Superior/efectos de los fármacos , Arteria Mesentérica Superior/metabolismo , Óxido Nítrico Sintasa/metabolismo , Ratas , Ratas Sprague-Dawley , Terlipresina , Factor de Necrosis Tumoral alfa/sangreAsunto(s)
Riñón/metabolismo , Potasio/metabolismo , Receptores de Vasopresinas/metabolismo , Animales , Desamino Arginina Vasopresina/farmacología , Femenino , Tasa de Filtración Glomerular , Iones , Riñón/efectos de los fármacos , Lipresina/análogos & derivados , Lipresina/farmacología , Potasio/orina , Ratas Wistar , Receptores de Vasopresinas/agonistasRESUMEN
OBJECTIVE: To evaluate the hemodynamic and metabolic effects of terlipressin and naloxone in cardiac arrest. METHODS: Cardiac arrest in rats was induced by asphyxia and maintained for 3.5 minutes. Animals were then resuscitated and randomized into one of six groups: placebo (n = 7), epinephrine (0.02 mg/kg; n = 7), naloxone (1 mg/kg; n = 7) or terlipressin, of which three different doses were tested: 50 µg/kg (TP50; n = 7), 100 µg/kg (TP100; n = 7) and 150 µg/kg (TP150; n = 7). Hemodynamic variables were measured at baseline and at 10 (T10), 20 (T20), 30 (T30), 45 (T45) and 60 (T60) minutes after cardiac arrest. Arterial blood samples were collected at T10, T30 and T60. RESULTS: The mean arterial pressure values in the TP50 group were higher than those in the epinephrine group at T10 (165 vs. 112 mmHg), T20 (160 vs. 82 mmHg), T30 (143 vs. 66 mmHg), T45 (119 vs. 67 mmHg) and T60 (96 vs. 66.8 mmHg). The blood lactate level was lower in the naloxone group than in the epinephrine group at T10 (5.15 vs. 10.5 mmol/L), T30 (2.57 vs. 5.24 mmol/L) and T60 (2.1 vs. 4.1 mmol/L). CONCLUSIONS: In this rat model of asphyxia-induced cardiac arrest, terlipressin and naloxone were effective vasopressors in cardiopulmonary resuscitation and presented better metabolic profiles than epinephrine. Terlipressin provided better hemodynamic stability than epinephrine.
Asunto(s)
Epinefrina/farmacología , Paro Cardíaco/tratamiento farmacológico , Lipresina/análogos & derivados , Modelos Animales , Naloxona/farmacología , Vasoconstrictores/farmacología , Animales , Presión Arterial/efectos de los fármacos , Asfixia/complicaciones , Reanimación Cardiopulmonar , Epinefrina/metabolismo , Paro Cardíaco/etiología , Paro Cardíaco/fisiopatología , Hemodinámica/efectos de los fármacos , Lipresina/metabolismo , Lipresina/farmacología , Masculino , Naloxona/metabolismo , Distribución Aleatoria , Ratas , Ratas Wistar , Valores de Referencia , Reproducibilidad de los Resultados , Terlipresina , Factores de Tiempo , Vasoconstrictores/metabolismoRESUMEN
Terlipressin is a vasopressin analogue. The clinical effect is attributable to affinity to vasopressin-1a receptors. However, it also has affinity to renal vasopressin-2 receptors, which can lead to water retention and dilutional hyponatraemia. We report a case of severe hyponatraemia secondary to terlipressin treatment. A 60-year-old woman with bleeding oesophageal varices was treated with terlipressin 2 mg every fourth hour. After 24 hours of treatment she was somnolent, and the sodium concentration had dropped from 127 mmol/l to 107 mmol/l. Hyponatraemia is an important adverse event in terlipressin treatment, and serum sodium should be monitored closely.
Asunto(s)
Hiponatremia/inducido químicamente , Lipresina/análogos & derivados , Vasoconstrictores/efectos adversos , Várices Esofágicas y Gástricas/complicaciones , Femenino , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Humanos , Hiponatremia/terapia , Lipresina/efectos adversos , Lipresina/farmacología , Lipresina/uso terapéutico , Persona de Mediana Edad , Sodio/sangre , Terlipresina , Vasoconstrictores/farmacología , Vasoconstrictores/uso terapéuticoRESUMEN
BACKGROUND: End-stage liver disease is associated with marked hemodynamic disturbances that are further aggravated during liver transplantation. Terlipressin has been shown to be effective in the management of sepsis-induced hypotension and hepatorenal syndrome and recently has been tried as infusion during liver transplantation. This study assessed the effect of intraoperative and postoperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during adult living donor liver transplantation. METHODS: Eighty recipients were randomly allocated into control (C group; n=40) and terlipressin (TP group; n=40), in which, terlipressin infusion was started at the beginning of surgery at a dose of 3 µg kg(-1) h(-1) to be reduced to 1.5 µg kg(-1) h(-1) after reperfusion and continued for 3 postoperative days; vasoactive agents were used as appropriate in all patients. Systemic hemodynamics, hepatic and renal arterial resistive indices (HARI, RARI), and portal venous blood flow (PBF) were compared between both groups intraoperatively and for 5 postoperative days. RESULTS: With terlipressin infusion, there were significant increases in both mean arterial pressure and systemic vascular resistance (P<.001), whereas heart rate and cardiac output decreased significantly (P<.001) throughout the study period compared with the C group. Vasoconstrictor drugs required during reperfusion were significantly lower in the TP group. There was a significant decrease in HARI, RARI, and portal venous blood flow in the TP group compared with the C group throughout the study period. There was no significant difference between both groups regarding liver function tests and serum lactate, whereas renal function tests were significantly better in the TP group. CONCLUSION: Terlipressin infusion significantly decreased HARI, RARI, and portal vein flow and improved low systemic vascular resistance and mean arterial pressure. It helped to reduce intraoperative vasoactive support and might improve postoperative renal function.
Asunto(s)
Hemodinámica/efectos de los fármacos , Circulación Hepática/efectos de los fármacos , Trasplante de Hígado , Donadores Vivos , Lipresina/análogos & derivados , Circulación Renal/efectos de los fármacos , Vasoconstrictores/farmacología , Femenino , Humanos , Lipresina/farmacología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , TerlipresinaRESUMEN
BACKGROUND AND AIM: The hemodynamics of patients with portal hypertension within 4 h after a single injection of terlipressin has been studied. However, the hemodynamics in a longer phase under different infusion styles is unknown. This study aims to compare the effects of bolus and continuous infusion of terlipressin on systemic and hepatic hemodynamics in patients with portal hypertension. METHODS: Twenty patients who underwent transjugular intrahepatic portosystemic shunt procedure were randomly assigned to be treated with either intravenous bolus infusion of terlipressin (1 mg) followed by a continuous infusion (4 mg/24 h, n = 10), or intravenous bolus injection of terlipressin (2 mg) followed by intermittent injections (1 mg/6 h, n = 10). The mean arterial pressure, heart rate, and portal venous pressure (PVP) were monitored and recorded at baseline, 1 min, 5 min, 10 min, 30 min, and then once an hour. Serum renin activity, serum angiotensin II, and aldosterone levels were measured prior to and 24 h after the administration of terlipressin. RESULTS: PVP dropped rapidly in both groups, and reduced 16.46% and 28.22%, respectively, at the 1-h time point. Thereafter, PVP remained stable in continuous group while rebounded obviously in intermittent group. One hour after the start of drug administration, heart rate decreased significantly in both groups (84.1 ± 12.8 vs 73.8 ± 12.6 in intermittent group and 86.7 ± 11.5 vs 77.1 ± 13.6 in continuous group, P < 0.005), and mean arterial pressure increased in both groups, although no statistical differences were found. CONCLUSION: Continuous infusion of terlipressin reduces PVP stably and may become an alternative to traditional bolus injection.